World Heart Novacor LVAS Transplant Alternative Trial Enrollment At 28
This article was originally published in The Gray Sheet
Executive Summary
World Heart has enrolled 28 out of 40 patients to be evaluated in the feasibility phase of its INTrEPID trial for its Novacor left ventricular assist system as an alternative-to-transplant destination therapy
You may also be interested in...
LVAD Developers Look To Medicare Coverage Decision To Offset Trial Costs
Launch of clinical trials for the DeBakey LVAD as destination therapy for end-stage heart failure patients is contingent on CMS issuing a national coverage decision for the expanded claim, MicroMed maintains
LVAD Developers Look To Medicare Coverage Decision To Offset Trial Costs
Launch of clinical trials for the DeBakey LVAD as destination therapy for end-stage heart failure patients is contingent on CMS issuing a national coverage decision for the expanded claim, MicroMed maintains
WorldHeart/Edwards Pump Up Novacor As Destination Therapy In Europe
WorldHeart and marketing partner Edwards Lifesciences will promote the Novacor left ventricular assist device (LVAD) as a destination therapy for heart failure patients in Europe following CE mark approval of a package of device enhancements, expected by the end of May